(MM) (TRGT) Quote

TRGT got smoked today.

TRGT $2.38 - Taking a medium position here as a real safe, real long shot ebola play with a 'Cash minus Total Liabilities' number of $3.38.

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001193125-14-300016%2Etxt&FilePath=%5C2014%5C08%5C07%5C&CoName=TARGACEPT+INC&FormType=10-Q&RcvdDate=8%2F7%2F2014&pdf=

With an estimated quarterly cash burn of (.25), it provides several months of comfort.

It was on their website
Also it dropped big today

Most of the drop in price occurred before any news release that I could find. Also trading stopped for about an hour. (Until an offical news release?) All the volume was buying after the drop.

they discontinued their alhziemers drug after phase 2 because it did not show it was more effective than current treatment.

Somebody dumped shares today.

Trending to a move to 5.60 near term. Huge 2.5 yr base and this stock may see higher price movement going into the 2nd half of the year.

Big volume last week, only means one thing, a move north is near.

I'm in! Phase 2b data due to be completed for ADZ3480 Alzheimers and TC-5214 Overactive Bladder by mid 2014

I am long TRGT. Why? Just announced failed phase 2 trial and stock got wallopped. Not sure what prospects the stock has going forward but its trading at cash value. Market cap of $157 million versus $143 million in cash as of 12/31/2013. More importantly in the last quarter Wellington Management, Vanguard, Deerfield Management, Dimensional fund, DE Shaw, State Street, Fidelity, and Goldman Sachs all initiated or increased existing positions. Something is most certainly up. Value investors should be looking.

Whew, that fall looks like a bad dream, only it's not a dream. It broke one year support, so who knows where this will keep falling to. Any want to throw the dice on a huge correct? Sure, after I see a definite CONFIRMED ( days) reverse. Otherwise head on down to the casino.

This thing sh*t the bed big time

This could get ugly here!!

$TRGT ~ Trendbuilding!!



Daily Par Sar Buy Signal ~ Criteria alert triggered during a recent trading session!

$TRGT has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~







For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~

What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~


To find other similar posts of "TRGT" utilize the links that follow.
Search MACDgyver's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ParSarBuyScan ~
Search MACDgyver's posts for symbol "TRGT": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=TRGT ~
Search Ihub for "TRGT" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=TRGT ~


For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~


Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~


c

7:50AM Targacept reports EPS in-line (TRGT) 5.21 : Reports Q2 (Jun) GAAP loss of $0.37 per share, in-line with the GAAP Capital IQ Consensus Estimate consensus of ($0.37). No revs were reported

"With recruitment completed this quarter in two ongoing Phase 2b clinical trials and tracking ahead of our initial planning assumptions in a third, we anticipate having three clinical readouts between December 2013 and the middle of 2014. Specifically, we expect to report top-line results from our study of TC-5619 as a treatment for negative symptoms and cognitive dysfunction in schizophrenia in either December 2013 or January 2014, top-line results from our study of TC-5214 as a treatment for overactive bladder in the first half of 2014 and top-line results from our study of TC-1734 in mild to moderate Alzheimer's disease in mid-2014,"

~ $TRGT ~ Daily Par Sar Buy Signal ~ Criteria alert triggered during a recent trading session!

$TRGT has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~







For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~

What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~


To find other similar posts of "TRGT" utilize the links that follow.
Search MACDgyver's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ParSarBuyScan ~
Search MACDgyver's posts for symbol "TRGT": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=TRGT ~
Search Ihub for "TRGT" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=TRGT ~


For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~


Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~


c

7:37AM Targacept beats by $0.09, beats on revs (TRGT) 4.78 : Reports Q1 (Mar) loss of $0.24 per share, $0.09 better than the Capital IQ Consensus Estimate of ($0.33); revenues fell 84.7% year/year to $3.5 mln vs the $0.6 mln consensus.

maybe this will get back on track now

Just wanted to drop a line to say Thank You surf1977 for the informative info updates you've been providing helping us all pick some bio-stocks! Keep it up!

7:06AM Targacept and AstraZeneca (AZN) amend collaboration; Targacept now has the right to pursue development and commercialization of any alpha7 NNR modulator (TRGT) 4.28 : The cos announced that its collaboration with AstraZeneca has been restructured. Under the new terms:

Targacept now has the right to pursue development and commercialization of any alpha7 NNR modulator in any therapeutic area, including cognitive disorders and schizophrenia, without obligation to AstraZeneca. Previously, AstraZeneca held an option to license any such compound that was developed by Targacept for a cognitive disorder or schizophrenia. Targacept has several alpha7 NNR modulators in its portfolio.
AstraZeneca now has the right to develop and commercialize the alpha4beta2 NNR modulators that it has licensed from Targacept under the collaboration, including AZD1446, in any therapeutic area. Previously, AstraZeneca's rights with regard to these compounds were limited to cognitive disorders and schizophrenia.
AstraZeneca will return to Targacept all rights to the alpha4beta2 modulator TC-1734 (also known as AZD3480), which is currently in a Phase 2b clinical trial in mild to moderate Alzheimer's disease.

Would be nice to see a move over $5 soon here

http://www.targacept.com/wt/page/news_calendar

8:56AM Targacept appoints Stephen Hill President and Chief Executive Officer (TRGT) 4.01 : Co announced that Stephen A. Hill, M.D. has been appointed as President and Chief Executive Officer. Dr. Hill is expected to start with Targacept on December 1, 2012 and will also join Targacept's Board of Directors. Hill currently serves as non-executive Chairman of the Board of Directors of each of Novelos Therapeutics (NVLT). Dr. Hill served previously as President and Chief Executive Officer of Solvay Pharmaceuticals, Inc. and ArQule (ARQL).

Didnt meet the primary objective

UPDATE 1-Targacept attention deficit drug fails study; jobs cut
Reuters - UK FocusReuters - UK Focus – 2 hours 1 minute ago

Email
Print

Companies:

ASTRAZENECA
Targacept Inc.

RELATED QUOTES
Symbol Price Change
AZN.L 2,888.50 -4.50
TRGT 4.31 -0.54

* Targacept ADHD drug fails to meet goal of mid-stage trial

* Company to cut undisclosed number of jobs

* Targacept (NasdaqGM: TRGT - news) to limit development of nicotinic pipeline

* Shares fall as much as 12.4 percent (Adds background about previous drug failures, adds bullet points)

Sept 17 (Reuters) - An experimental treatment for attention deficit hyperactivity disorder from Targacept Inc did not meet the main goal of a mid-stage trial, prompting the company to drop development of the drug and cut jobs.

Targacept shares fell as much as 12.4 percent on Monday after the results showed that patients in the placebo group had improved more than those taking the experimental drug, TC-5619.

The company did not specify how many people it would lay off, but said it would limit investment in the development of certain products in its pipeline until it appoints a new chief executive officer.

In June, CEO Donald deBethizy stepped down. His role is being assumed by Chairman Mark Skaletsky pending the appointment of a new CEO.

DeBethizy's departure followed disappointing results from trials of Targacept's treatments for diabetes and asthma, which prompted the company to cut its workforce by 46 percent, or 65 jobs.

In March, Targacept and partner AstraZeneca (LSE: AZN.L - news) said they would abandon work on the their experimental antidepressant after it failed to meet key goals in two late-stage clinical studies.

Targacept shares were down 10.7 percent at $4.33 in Monday morning trading after falling to $4.25 earlier in the session. (Reporting by Vidya P L Nathan in Bangalore and Toni Clarke in Boston; Editing by Joyjeet Das and Lisa Von Ahn)'

9:16AM Targacept reports top-line results from Phase 2 Trial of TC-5619 in adults with inattentive- predominant ADHD; TC-5619 did not meet the primary outcome (TRGT) 4.84 : Co announces top-line results from a Phase 2 trial of TC-5619 as a treatment for inattentive-predominant attention deficit/hyperactivity disorder. In the trial, TC-5619 did not meet the primary outcome measure, change from baseline on the inattention subscale of the Conners' Adult ADHD Rating Scale-Investigator-Rated, after four weeks of treatment versus placebo. Across the study measures, patients in the placebo dose group consistently improved more than patients in the TC-5619 dose groups. TC-5619 exhibited a placebo-like safety and tolerability profile in the study.

8:56AM Targacept announces plans to develop TC-5214 in overactive bladder (TRGT) 4.67 : Co announced that it plans to pursue development of TC-5214 as a treatment for overactive bladder. Based on TC-5214's unique pharmacokinetic profile, an analysis of data from a completed clinical program and findings from additional preclinical studies, the company plans to initiate a Phase 2b study of TC-5214 in the first half of 2013.

http://www.bizjournals.com/triad/news/2012/06/18/debethizy-to-get-one-year-salary-from.html?ana=yfcpc

Wow.. High volume with a lot of large buys.. Interesting.

8:57AM Targacept announces revised top-line results from exploratory Phase 2 study of TC-6987 in asthma: study no longer achieves protocol-defined success criteria on primary endpoint of Forced Expiratory Volume (TRGT) 4.85 : Co announced revised top-line results from its exploratory Phase 2 clinical study of TC-6987 in asthma. Following identification of an error in the application of the agreed statistical analysis plan, a reanalysis of the data was undertaken. As compared to the initially reported values, the reanalysis revealed a 2 ml decrease in the change in Forced Expiratory Volume (FEV1) from baseline to pre-dosing on day 28, which resulted in TC-6987 no longer achieving the study's protocol-defined success criteria on that co-primary endpoint. However, TC-6987 continued in the reanalysis to meet protocol-defined success criteria on the study's other co-primary endpoint, change in FEV1 from baseline to two hours post-dosing on day 28. Reanalysis of the post-dose measure revealed an incrementally stronger signal of a drug effect than the initial analysis.

8:06AM Targacept announces 'Top-line' results from two exploratory Phase 2 studies of TC-6987; co will not pursue further development of TC-6987 as a treatment for diabetes (TRGT) 5.41 : Co announced top-line results from two separate exploratory Phase 2 studies of its product candidate TC-6987 conducted in the United States, one in asthma and one in type 2 diabetes. In the asthma study, oral TC-6987 met protocol-defined success criteria on both co-primary outcome measures, change from baseline in forced expiratory volume for adjunct TC-6987 compared to adjunct placebo measured at two time points on day 28. TC-6987 was generally well tolerated in both studies. There were no clinically meaningful changes in cardiovascular parameters in either study, an important finding that differentiates TC-6987 from many other alpha7 modulators. Co-Primary Endpoints in Asthma Study Achieved. In the type 2 diabetes study, the primary outcome measure, change in fasting plasma glucose, was not met, and Targacept will not pursue further development of TC-6987 as a treatment for diabetes. TC-6987 is a modulator of the alpha7 neuronal nicotinic receptor discovered by Targacept scientists using Pentad, the company's proprietary drug discovery platform.

Yeah morning wi be key but TRGT will need to give some positive news in the coming days tho. Hopefully it doesn't go under 5.

$TRGT, Gappy McGapperson? http://blog.chartmystock.com/2012/03/20/trgt-gaptastic-or-a-falling-knife-3.aspx

Yup,lets see in the morning if it tries to test under 5, hope not but its possible,will add at 5+4.75 to top off position,would rather not thou,lol

Yeah that's true.. Todays news was a killer but again like you said what analysts will say in regards to cash position or pipeline will be key. Definately not going to 30s, but yeah yesterday's close price would be great. If we can positive results in summer and get closer to production for even 1 drug that would be awesome.

Well TRGT actually trading below cash ,really beat up on the phase 3 failure,but they have a few other phase 2s due by summer ,should rebound a bit if some analysts sound off on cash and potential,not going back to 30 but 7 or so would be nice,would hopefully like to ride a few free and then lets chips fall where they may with the rest of their pipeline

Oh good... I just took a small position.. Yeah hopefully we get a good bounce or some news about some new product.

Nice buy,i'm in 5.37 avg,lets get a nice bounce...soon

~ well, this stock was trading at $30 about a year ago... so, it looks very cheap at $5 ... maybe i'm wrong... (been wrong many times before... haha)

~ good luck to you :)

Thanks.. May need all the luck I can get. I bought it to catch the bounce but am trying to figure if this could be a long hold. Quick question: why would you say it's a great price? They dont have any products on the shelf and far from getting one on it. Confused at this point.. Hmmm

~ not sure about tomorrow, but in my opinion 5.18 is a good price...

here is a good post from another poster for your reference...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=73493690

~ good luck to you :)

You think so? I was gonna buy in at 5.55 but waited and briefly saw 5.15s print and got caught up for work and when I came back to my pc; saw 5.20's so I thought might be primed for a bounce and luckily my 5.18 got filled

wow $5.18 is a very nice price, i think..

Hmmm yeah that's what I am looking for; a bounce.. That would be good. I was able to get in at 5.18. I might hold it for a couple of months if it doesn't bounce in the next couple of weeks.

~ good question, i think
i played as a quick bounce play last november... but it didn't bounce much ... not sure aboout this time, though... i'm just watching..

http://www.bizjournals.com/triad/news/2012/03/20/targacept-time-to-broaden-search-for.html

Can't decide whether to buy or not.. Quite speculative.. No products on the shelf yet and no other drugs close to complete. No dividends either.. Opinions..

Astra quits but TRGT prepared; Purse other avenues with 225 m. cash!
AstraZeneca, Targacept end work on depression drug
AstraZeneca, Targacept ending development of depression drug after disappointing trial
Associated PressAssociated Press – 6 minutes ago


Targacept, Inc.

RELATED QUOTES
Symbol Price Change
TRGT 5.695 -1.71

LONDON (AP) -- Drug makers AstraZeneca and North Carolina-based Targacept have abandoned plans to seek regulatory approval for a drug intended to treat major depressive disorder, the companies said Tuesday.

AstraZeneca said that the drug TC-5214 did not perform as hoped in an eight-week trial compared to a placebo. The announcement caused little surprise, following disappointing trials last year, but was a blow nevertheless for Targacept, the smaller of the two companies. Its shares dropped 14 percent in premarket trading in New York.

AstraZeneca, which said it will take an impairment charge of $50 million on the drug's failure, saw its shares fall only 1 percent to 2,830 pence in London.

TC-5214, which was not expected to be a blockbuster, was being tested as a supplementary treatment for major depressive disorder in patients who did not respond to the most common type of antidepressants, selective serotonin reuptake inhibitors. It was intended to work on neuronal nicotinic receptors, which regulate the nervous system.

Had the drug succeeded, sales would have been less than $100 million a year in 2016, according to analyst projections.

Dr. Mike Mitchell, health care expert at Seymour Pierce & Co., said the news underlined the difficulties of making progress in neuroscience.

"This is a tough field in which to develop new drugs, where current knowledge of the underlying biology of pathologies appears to be insufficient to generate reliable drug targets," Mitchell said.

Sanofi, GlaxoSmithKline, Merck, Novartis had cut back on research and development in the past two years, Mitchell noted. AstraZenecase earlier announced it was closing research labs in Canada and Sweden.

London-based AstraZeneca and Targacept Inc., based in Winston-Salem, North Carolina, signed a collaboration agreement to develop the drug in 2009.

J. Donald deBethizy, Targacept's president and chief executive officer, said the company had been reviewing its business to prepare for the possible failure of the drug, and had more than $225 million in cash to purse other avenues.

In @ $6.08

4:08AM Targacept and AstraZeneca (AZN) announce remaining TC-5214 Phase 3 efficacy studies do not meet primary endpoint; regulatory filing will not be pursued (TRGT) 7.41 : AstraZeneca (AZN) and Targacept announce top-line results from the remaining Phase 3 studies investigating efficacy, tolerability and safety of TC-5214 as an adjunct therapy to an antidepressant in patients with major depressive disorder who did not respond adequately to initial antidepressant treatment. RENAISSANCE 4 and RENAISSANCE 5, both efficacy and tolerability studies, did not meet the primary endpoint of change on the Montgomery-Asberg Depression Rating Scale total score after eight weeks of adjunct treatment with TC-5214 as compared to placebo. These studies conclude the RENAISSANCE Program for TC-5214. Based on the totality of the results, AstraZeneca and Targacept will not pursue a regulatory filing for TC-5214 as an adjunct treatment for patients with MDD.

~ $TRGT ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $TRGT ~ Earnings expected on Monday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=TRGT&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=TRGT&p=W&b=3&g=0&id=p54550695994



~ Barchart: http://barchart.com/quotes/stocks/TRGT?
~ OTC Markets: http://www.otcmarkets.com/stock/TRGT/company-info
~ Google Finance: http://www.google.com/finance?q=TRGT
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=TRGT#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=TRGT+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=TRGT
Finviz: http://finviz.com/quote.ashx?t=TRGT
~ BusyStock: http://busystock.com/i.php?s=TRGT&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=TRGT&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=TRGT
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=TRGT
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=TRGT
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=TRGT
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=TRGT
~ MarketWatch: http://www.marketwatch.com/investing/stock/TRGT/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=TRGT
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=TRGT
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=TRGT&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=TRGT&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=TRGT&size=l&frequency=60&color=g


http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.